TP53 and B-cell chronic lymphocytic leukemia: The rationale behind targeting the p53 pathway in CLL is grounded in the relatively low frequency of TP53 alterations at diagnosis (approximately 10%), which suggests that a significant portion of CLL cases could benefit from therapies aimed at activating p53 function.